ORGOVYX® WAS GENERALLY WELL TOLERATED¹

ADVERSE REACTIONS (≥ 5%) OF PATIENTS WITH ADVANCED PROSTATE CANCER
WHO RECEIVED ORGOVYX® IN THE HERO STUDY

Adapted from the Product Monograph.¹

a Includes diarrhea and colitis.
b Includes fatigue and asthenia.
c Includes arthralgia, back pain, pain in extremity, musculoskeletal pain, myalgia, bone pain, neck pain, arthritis, musculoskeletal stiffness, non-cardiac chest pain,
musculoskeletal chest pain, spinal pain, and musculoskeletal discomfort.

Permanent discontinuation due to an adverse reaction occurred in 3.5% of patients receiving ORGOVYX®.
Serious adverse reactions occurred in 12% of patients receiving ORGOVYX®.

Check out the HERO
study publication.

Efficacy Profile

Evaluate the ORGOVYX® efficacy data from the HERO study.

Dosing and Administration

Find dosing and administration information related to ORGOVYX®.

Reference: 1. ORGOVYX® Product Monograph. Sumitomo Pharma Switzerland GmbH. November 3, 2023.

ORGOVYX® WAS GENERALLY WELL TOLERATED1